Arcutis Biotherapeutics, Inc. (ARQT)
- Previous Close
8.59 - Open
8.59 - Bid 8.45 x 800
- Ask 8.48 x 800
- Day's Range
8.38 - 8.85 - 52 Week Range
1.76 - 15.21 - Volume
2,163,225 - Avg. Volume
4,299,815 - Market Cap (intraday)
973.804M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-3.78 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
www.arcutis.comRecent News: ARQT
Performance Overview: ARQT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARQT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARQT
Valuation Measures
Market Cap
973.81M
Enterprise Value
907.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.85
Price/Book (mrq)
10.98
Enterprise Value/Revenue
15.23
Enterprise Value/EBITDA
-3.99
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.12%
Return on Equity (ttm)
-175.79%
Revenue (ttm)
59.61M
Net Income Avi to Common (ttm)
-262.14M
Diluted EPS (ttm)
-3.78
Balance Sheet and Cash Flow
Total Cash (mrq)
271.86M
Total Debt/Equity (mrq)
232.24%
Levered Free Cash Flow (ttm)
-151.32M